Compare VOXR & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VOXR | ALLO |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.7M | 252.9M |
| IPO Year | N/A | 2018 |
| Metric | VOXR | ALLO |
|---|---|---|
| Price | $4.60 | $1.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $8.60 |
| AVG Volume (30 Days) | 684.4K | ★ 2.9M |
| Earning Date | 02-19-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,158,304.00 | N/A |
| Revenue This Year | $42.80 | N/A |
| Revenue Next Year | $82.76 | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.06 | N/A |
| 52 Week Low | $2.21 | $0.86 |
| 52 Week High | $5.54 | $3.78 |
| Indicator | VOXR | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 41.26 | 59.13 |
| Support Level | $4.44 | $1.30 |
| Resistance Level | $4.91 | $1.54 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 15.31 | 85.71 |
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.